Best Practice & Research Clinical Anaesthesiology
Volume 23, Issue 4 , Pages 431-439 , December 2009

Clinical benefits of tight glycaemic control: effect on the kidney

  • Jan Gunst, MD
    • ,
  • Miet Schetz, MD, PhD

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +32 16 344021; Fax: +32 16 344015.

References 

  1. Bellomo R, Ronco C, Kellum JA, et al., the ADQI workgroup  Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care. 2004;8:R204–R212
  2. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet. 2005;365:417–430
  3. Coca SG, Yusuf B, Shlipak MG, et al. Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. American Journal of Kidney Diseases. 2009;53:961–973
  4. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney International. 2008;73:538–546
  5. Lameire N, Van Biesen W, Vanholder R. Acute kidney injury. Lancet. 2008;372:1863–1865
  6. Venkataraman R, Kellum JA. Prevention of acute renal failure. Chest. 2007;131:300–308
  7. Wolf G. New insights into the pathophysiology of diabetic nephropathy: from haemodynamics to molecular pathology. European Journal of Clinical Investigation. 2004;34:785–796
  8. Caramori ML, Mauer M. Diabetes and nephropathy. Current Opinion in Nephrology and Hypertension. 2003;12:273–282
  9. Schrijvers BF, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: the role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocrine Reviews. 2004;25:971–1010
  10. Singh DK, Winocour P, Farrington K. Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy. Nature Clinical Practice. Nephrology. 2008;4:216–226
  11. Wang S, Mitu GM, Hirschberg R. Osmotic polyuria: an overlooked mechanism in diabetic nephropathy. Nephrology, Dialysis, Transplantation. 2008;23:2167–2172
  12. Action to Control Cardiovascular Risk in Diabetes Study Group , Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. The New England Journal of Medicine. 2008;358:2545–2559
  13. ADVANCE Collaborative Group , Patel A, MacMahon S, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. The New England Journal of Medicine. 2008;358:2560–2572
  14. Duckworth W, Abraira C, Moritz T, et al., VDAT Investigators  Glucose control and vascular complications in veterans with type 2 diabetes. The New England Journal of Medicine. 2009;360:129–139
  15. The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The New England Journal of Medicine. 1993;329:977–986
  16. The Diabetes Control and Complications (DCCT) Research Group . Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney International. 1995;47:1703–1720
  17. U.K. Prospective Diabetes Study Group . Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk for complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853
  18. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group . Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA : The Journal of the American Medical Association. 2003;290:2159–2167
  19. Fioretto P, Bruseghin M, Berto I, et al. Renal protection in diabetes: role of glycaemic control. Journal of the American Society of Nephrology. 2006;17:S86–S89
  20. Mizock BA. Alterations in fuel metabolism in critical illness: hyperglycaemia. Best Practice & Research. Clinical Endocrinology & Metabolism. 2001;15:533–551
  21. Bagshaw SM, Egi M, George C, Bellomo R, the ANZICS Database Management Committee . Early blood glucose control and mortality in critically ill patients in Australia. Critical Care Medcine. 2009;37:463–470
  22. Kosiborod M, Rathore SS, Inzucchi SE, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation. 2005;111:3078–3086
  23. Gandhi GY, Nuttall GA, Abel MD, et al. Intraoperative hyperglycemia and perioperative outcomes in cardiac surgery patients. Mayo Clinic Proceedings. Mayo Clinic. 2005;80:862–866
  24. Mangano CM, Diamondstone LS, Ramsay JG, et al. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Annals of Internal Medicine. 1998;128:194–203
  25. Turcot DB, Kiernan FJ, McKay RG, et al. Acute hyperglycemia: implications for contrast-induced nephropathy during cardiac catheterization. Diabetes Care. 2004;27:620–621
  26. Cheung NW, Napier B, Zaccaria C, et al. Hyperglycemia is associated with adverse outcomes in patients receiving total parenteral nutrition. Diabetes Care. 2005;28:2367–2371
  27. Lin LY, Lin HC, Lee PC, et al. Hyperglycemia correlates with outcomes in patients receiving total parenteral nutrition. The American Journal of the Medical Sciences. 2007;333:261–265
  28. Blasi-Ibanez A, Hirose R, Feiner J, et al. Predictors associated with terminal renal function in deceased organ donors in the intensive care unit. Anesthesiology. 2009;110:333–341
  29. Hirose R, Xu F, Dang K, et al. Transient hyperglycemia affects the extent of ischemia-reperfusion-induced renal injury in rats. Anesthesiology. 2008;108:402–414
  30. Moursi M, Rising CL, Zelenock GB, et al. Dextrose administration exacerbates acute renal ischemic damage in anesthetized dogs. Archives of Surgery. 1987;122:790–804
  31. Podrazik RM, Natale JE, Zelenock GB, et al. Hyperglycemia exacerbates and insulin fails to protect in acute renal ischemia in the rat. The Journal of Surgical Research. 1989;46:572–578
  32. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. The New England Journal of Medicine. 2001;345:1359–1367
  33. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. The New England Journal of Medicine. 2006;354:449–461
  34. American Diabetes Association . Standards of medical care in diabetes - 2008. Diabetes Care. 2008;31(Suppl. 1):S12–S54
  35. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force . American association of clinical endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocrine Practice. 2007;13(Suppl. 1):1–68
  36. Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. Critical Care Medcine. 2008;36:296–327
  37. Rydén L, Standl E, Bartnik M, et al., Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) , European Association for the Study of Diabetes (EASD)  Guidelines on diabetes, pre-diabetes, and cardiovascular diseases; executive summary. European Heart Journal. 2007;28:88–136
  38. Devos P, Preiser J, Melot C. Impact of tight glucose control by intensive insulin therapy on ICU mortality and the rate of hypoglycaemia: final results of the glucontrol study (European Society of Intensive Care Medicine 20th Annual Congress abstract 0735). Intensive Care Medicine. 2007;33(Suppl. 2):S189
  39. Brunkhorst FM, Engel C, Bloos F, et al., German Competence Network Sepsis (SepNet)  Intensive insulin therapy and pentastarch resuscitation in severe sepsis. The New England Journal of Medicine. 2008;358:125–139
  40. Arabi YM, Dabbagh OC, Tamim HM, et al. Intensive versus conventional insulin therapy: a randomized controlled trial in medical and surgical critically ill patients. Critical Care Medcine. 2008;36:3190–3197
  41. De La Rosa GdC, Donado JH, Restrepo AH, et al. Strict glycaemic control in patients hospitalised in a mixed medical and surgical intensive care unit: a randomised clinical trial. Critical Care. 2008;12:R120
  42. Bilotta F, Caramia R, Paoloni FP, et al. Safety and efficacy of intensive insulin therapy in critical neurosurgical patients. Anesthesiology. 2009;110:611–619
  43. Finfer S, Chittock DR, Su SY, et al., NICE-SUGAR Study Investigators  Intensive versus conventional glucose control in critically ill patients. The New England Journal of Medicine. 2009;360:1283–1297
  44. Inzucchi SE, Siegel MD. Glucose control in the ICU – how tight is too tight?. The New England Journal of Medicine. 2009;360:1346–1349
  45. Preiser JC. NICE-SUGAR: the end of a sweet dream?. Critical Care. 2009;13:143
  46. Comi RJ. Glucose control in the intensive care unit: a roller coaster ride or a swinging pendulum?. Annals of Internal Medicine. 2009;150:809–811
  47. Fahy BG, Sheely AM, Coursin DB. Glucose control in the intensive care unit. Critical Care Medcine. 2009;37:1769–1776
  48. Van den Berghe G, Schetz M, Vlasselaers D, et al. Intensive insulin therapy in critically ill patients: NICE-SUGAR or Leuven blood glucose target? The Journal of Clinical Endocrinology and Metabolism, in press (PMID: 19531590).
  49. Schetz M, Vanhorebeek I, Wouters PJ, et al. Tight blood glucose control is renoprotective in critically ill patients. Journal of the American Society of Nephrology. 2008;19:571–578
  50. Van den Berghe G, Wilmer A, Milants I, et al. Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. Diabetes. 2006;55:3151–3159
  51. Krinsley JS. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clinic Proceedings. Mayo Clinic. 2004;79:992–1000[Erratum in: Mayo Clinic Proceedings. Mayo Clinic 2005; 80: 1101]
  52. Lecomte P, Van Vlem B, Coddens J, et al. Tight perioperative glucose control is associated with a reduction in renal impairment and renal failure in non-diabetic cardiac surgical patients. Critical Care. 2008;12:R154
  53. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA : The Journal of the American Medical Association. 2008;300:933–944
  54. Scott MG, Bruns DE, Boyd JC, Sacks DB. Tight glucose control in the intensive care unit: are glucose meters up to the task?. Clinical Chemistry. 2009;55:18–20
  55. Egi M, Bellomo R, Stachowski E, et al. Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology. 2006;105:244–252
  56. Krinsley JS. Glycemic variability: a strong independent predictor of mortality in critically ill patients. Critical Care Medcine. 2008;36:3008–3013
  57. Egi M, Bellomo R, Reade MC. Is reducing variability of blood glucose the real but hidden target of intensive insulin therapy?. Critical Care. 2009;13:302
  58. Ellger B, Debaveye Y, Vanhorebeek I, et al. Survival benefits of intensive insulin therapy in critical illness. Diabetes. 2006;55:1096–1105
  59. Devarajan P. Update on mechanisms of ischemic acute kidney injury. Journal of the American Society of Nephrology. 2006;17:1503–1520
  60. Chatterjee PK. Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2007;376:1–43
  61. Bonventre J. Ischemic acute renal failure: an inflammatory disease?. Kidney International. 2004;66:480–485
  62. Kaushal GP, Basnakian AG, Shah SV. Apoptotic pathways in ischemic acute renal failure. Kidney International. 2004;66:500–506
  63. Wan L, Bagshaw SM, Langenberg C, et al. Pathophysiology of septic acute kidney injury: what do we really know?. Critical Care Medcine. 2008;36(Suppl.):S198–S203
  64. Singer M. Mitochondrial function in sepsis: acute phase versus multiple organ failure. Critical Care Medcine. 2007;35(Suppl.):S441–S448
  65. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820
  66. Forbes M, Coughlan MT, Cooper ME. Oxidative stress as a major culprit in kidney disease in diabetes. Diabetes. 2008;57:1446–1454
  67. Ha H, Hwang IA, park JH, et al. Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Research and Clinical Practice. 2008;82(Suppl. 1):S42–S45
  68. Langouche L, Vander Perre S, Wouters P, Van den Berghe G. Expression of glucose transporters in critical illness. (abstract) Critical Care. 2006;10(Suppl. 1):P252
  69. Van den Berghe G. How does blood glucose control with insulin save lives in intensive care?. The Journal of Clinical Investigation. 2004;9:1187–1195
  70. Choi SW, Benzie IFF, Ma SW, et al. Acute hyperglycemia and oxidative stress: direct cause and effect?. Free Radical Biology & Medicine. 2008;44:1217–1231
  71. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA : The Journal of the American Medical Association. 2006;295:1681–1687
  72. Langouche L, Vanhorebeek I, Vlasselaers D, et al. Intensive insulin therapy protects the endothelium of critically ill patients. The Journal of Clinical Investigation. 2005;115:2277–2286
  73. Vanhorebeek I, De Vos R, Mesotten D, et al. Protection of hepatocyte mitochondrial ultrastructure and function by strict blood glucose control with insulin in critically ill patients. Lancet. 2005;365:53–59
  74. Vanhorebeek I, Gunst J, Ellger B, et al. Hyperglycemic damage to renal tissue in an animal model of prolonged critical illness. Kindey International. 2009;76:512–520
  75. Vanhorebeek I, Ellger B, De Vos R, et al. Tissue-specific glucose toxicity induces mitochondrial damage in a burn injury model of critical illness. Critical Care Medcine. 2009;37:1355–1364
  76. Dandona P, Chaudhuri A, Ghanim H, et al. Anti-inflammatory effects of insulin and the pro-inflammatory effects of glucose. Seminars in Thoracic and Cardiovascular Surgery. 2006;18:293–301
  77. Weekers F, Giulietti AP, Michalaki M, et al. Metabolic, endocrine, and immune effects of stress hyperglycemia in a rabbit model of prolonged critical illness. Endocrinology. 2003;144:5329–5338
  78. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clinical Science (London, England : 1979). 2005;109:143–159
  79. Molitoris BA, Sutton TA. Endothelial injury and dysfunction: role in the extension phase of acute renal failure. Kidney International. 2004;66:496–499
  80. Allen DA, Harwood S, Varagunam M, et al. High glucose-induced oxidative stress causes apoptosis in proximal tubular epithelial cells and is mediated by multiple caspases. The FASEB Journal. 2003;17:908–910
  81. Ortiz A, Ziyadeh FN, Neilson EG. Expression of apoptosis-regulatory genes in renal proximal tubular epithelial cells exposed to high ambient glucose and in diabetic kidneys. Journal of Investigative Medicine. 1997;45:50–56
  82. Samikkannu T, Thomas JJ, Bhat J, et al. Acute effect of high glucose on long term cell growth: a role for transient glucose increase in proximal tubule cell injury. American Journal of Physiology. Renal Physiology. 2006;291:F162–F175
  83. Meier M, Nitschke M, Hocke C, et al. Insulin inhibits caspase-3 activity in human renal tubular epithelial cells via the PI3-Kinase/Akt pathway. Cellular Physiology and Biochemistry. 2008;21:279–286
  84. Melin J, Hellberg O, Larsson E, et al. Protective effect of insulin on ischemic renal injury in diabetes mellitus. Kidney International. 2002;61:383–392
  85. Mesotten D, Swinnen JV, Vanderhoydonc F, et al. Contribution of circulating lipids to the improved outcome of critical illness by glycaemic control with intensive insulin therapy. The Journal of Clinical Endocrinology and Metabolism. 2004;89:219–226
  86. Thiemermann C, Patel NSA, Kvale EO, et al. High Density Lipoprotein (HDL) reduces renal ischemia/reperfusion injury. Journal of the American Society of Nephrology. 2003;14:1833–1843

PII: S1521-6896(09)00047-0

doi: 10.1016/j.bpa.2009.08.003

Best Practice & Research Clinical Anaesthesiology
Volume 23, Issue 4 , Pages 431-439 , December 2009

Article Tools